Data From Investigator-Sponsored Trial Of Oncophage(R) Cancer Vaccine In Glioma Presented At Immunotherapy Task Force Meeting
17th Nov 2006, 08:24 GMT
Antigenics Inc. (Nasdaq: AGEN) announced that preliminary data from a Phase 1/2 investigator- sponsored trial of the company's investigational cancer vaccine Oncophage(R) (vitespen; formerly HSPPC-96) as a treatment for recurrent glioma were presented at the Immunotherapy Task Force Meeting, held at the Society of Neuro-Oncology's 11th Annual Scientific Meeting. [click link for full article]
Latest news from Health News from Medical News Today:
- Biotech Industry Welcomes WHO Initiative On Naming Of Biologicals Including Biosimilar Medicines
- Common Cause Of Heart Disease, Diabetes May Be Treatable With Malaria Drug
- Two Nerve Cells In Direct Contact
- Value Of 'Helper' Compound In Treating Some Leukemias
- Internists Take Home Several National Awards At AAMC Annual Meeting
- Most Canadian Med School Grads Lack Basic Surgical Skills
- ACP's Electronic Medical Resource Ranked No. 1 Evidence-based Tool By MLA's South Central Chapter
- University Of Illinois Scientist Helping Processors Keep E. Coli Out Of Meat
- American Thoracic Society Publishes New Statement On Hepatotoxicity Of Antituberculosis Therapy
- Neural Networking Nanotubes